Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

LLY, NFLX, and GE lead today's top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and costs ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

LLY, NFLX, and GE lead this week???s top research picks as strong demand, growth strategies, and sector tailwinds fuel ...

Eli Lilly and Company (NYSE:LLY) is one of the high-margin pharma stocks to buy now. Eli Lilly and Company (NYSE:LLY) is set ...

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

The obstructive sleep apnea (OSA) market is being propelled by the rapid evolution of early detection and diagnostic tools. Technologies like home sl ...

Eli Lilly is advancing its Phase 2 clinical trial to test LY3841136 for weight management in obese and overweight adults.

If you wish to turn $10,000 into $50,000 by 2035, you’re looking at a 400% gain over a 10-year horizon. In the past decade, ...

This week, Phil Oakley has analysed two shares, DexCom (US:DXCM) and Auto Trader (AUTO), which have decent earnings growth forecasts but rich valuations. It looks like both companies will need ...